7/106 sources · 5 publishersUpdated Oct 8, 20:58 UTC
Harrow completes $30 million purchase of TYRVAYA nasal spray from Viatris
Harrow closed its acquisition of the TYRVAYA nasal spray, paying $30 million in cash and agreeing to up to $70 million in milestone payments. The deal gives Harrow worldwide rights to the dry‑eye treatment except in Japan, where Viatris keeps commercial rights and will pay royalties. About 40 Viatris staff will join Harrow’s ocular‑surface team in Q4 2026.
Why it matters
Harrow said the addition should generate more than $30 million of revenue in 2027, expanding its dry‑eye portfolio alongside VEVYE. The transaction also adds a new product line and a larger sales force, which could improve market reach and earnings potential.
Key facts
- 1Harrow paid $30 million in cash at closing. globenewswire.com
- 2The agreement includes up to $70 million in contingent milestone payments, for a possible total consideration of up to $100 million. globenewswire.com
- 3Harrow acquired worldwide rights to TYRVAYA except for Japan. globenewswire.com
- 4Viatris retained Japanese commercialization rights and will pay royalties on any future net sales there. globenewswire.com
- 5Approximately 40 Viatris employees are expected to join Harrow’s ocular‑surface commercial team, with onboarding in the fourth quarter of 2026. globenewswire.com
- 6Harrow expects TYRVAYA to generate more than $30 million in revenue in 2027. globenewswire.com
Summary written by AlphAI from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.